A monoclonal antibody W1 blocks mesothelin-mediated tumor progression
{{output}}
Mesothelin (MSLN) represents an attractive and potential biomarker for targeted cancer therapy. Although MSLN has been implicated in mediating tumorigenesis, its precise physiological function remains incompletely elucidated. Moreover, only a limited number of... ...